centuri
rapid
spread
cure
infecti
diseas
major
concern
progress
surviv
human
diseas
global
burden
promin
caus
worldwid
death
disabl
nanomedicin
emerg
excel
tool
erad
halt
spread
variou
nanoformul
nf
use
advanc
nanotechnolog
demand
recent
hydrogel
nanogel
base
drug
deliveri
devic
pose
new
prospect
simul
natur
intellig
variou
biolog
system
owe
uniqu
porou
interpenetr
network
design
hydrophob
drug
incorpor
stimulu
sensit
hydrogel
owe
excel
potenti
target
drug
deliveri
system
present
review
attempt
highlight
recent
trend
hydrogel
base
drug
deliveri
system
deliveri
therapeut
agent
diagnost
major
infecti
diseas
includ
acquir
immun
defici
syndrom
aid
malaria
tuberculosi
influenza
ebola
futur
prospect
challeng
also
brief
nanomedicin
activ
target
locat
use
variou
nf
dd
includ
nanoparticl
polymer
micel
nanorod
nanospher
solid
lipid
nanoparticl
nanolipososm
dendrim
metal
nanoparticl
fulleren
quantum
dot
nf
use
develop
variou
differ
rout
like
system
oral
pulmonari
transderm
help
drug
target
ondemand
drug
deliveri
techniqu
technolog
vashist
et
al
last
centuri
human
handicap
sudden
epidem
emerg
infecti
diseas
make
curiou
seek
growth
develop
new
vaccin
antimicrobi
thu
present
devot
toward
nanomedicin
nanotechnolog
base
therapeut
emerg
infect
ei
basic
defin
infect
arous
popul
exist
previous
continu
spread
geograph
rang
infecti
diseas
consid
third
lead
caus
death
us
earli
human
immunodefici
viru
hiv
initi
accept
infect
estim
million
peopl
worldwid
unaid
epidem
updat
lead
aid
despit
new
advanc
field
antiinfecti
agent
recent
year
treatment
varieti
bacteri
fungal
infect
well
parasit
viral
diseas
uphold
great
challeng
basic
understand
infecti
diseas
describ
disord
occur
presenc
pathogen
agent
includ
viru
bacterium
fungu
infecti
diseas
come
categori
communic
diseas
transfer
one
person
includ
dengu
malaria
tuberculosi
wherea
transfer
occur
one
speci
flu
influenza
occur
diseas
broadli
classifi
firstli
diseas
firmli
persist
like
malaria
tuberculosi
secondli
earlier
unknown
diseas
like
sever
acut
respiratori
syndrom
lastli
diseas
threaten
enhanc
near
futur
eg
avian
influenza
develop
countri
major
suffer
half
death
happen
due
infecti
diseas
better
understand
need
gather
knowledg
bacteri
pathogen
classifi
extracellular
intracellular
pathogen
basi
vivo
life
pathogen
main
target
local
diseas
inflamm
infect
overexpress
epitop
receptor
initi
use
antibiot
penicillin
late
great
success
advanc
stronger
antibiot
begun
though
resist
antimicrobi
drug
threat
hospit
commun
number
effect
drug
control
infect
old
bacteria
decreas
thu
invent
nano
carrier
system
offer
antibiot
deliv
select
phagocyt
cell
increas
cellular
penetr
treatment
intracellular
infect
factor
behind
infect
includ
number
aspect
owe
chang
environ
increas
frequenc
contact
host
carri
infect
thu
increas
chanc
encount
microorgan
formerli
unfamiliar
be
tuberculosi
tb
one
fear
diseas
discoveri
antibiot
caus
larg
scale
human
death
last
year
research
urg
discov
nanotechnolog
base
drug
carrier
smart
materi
nano
micro
gel
insid
cargo
encapsul
give
sustain
releas
drug
rather
convent
free
drug
deliveri
present
articl
one
section
deal
brief
overview
diseas
variou
benefit
hydrogel
base
drug
deliveri
system
dd
tb
encapsul
variou
cargo
insid
nf
main
attent
owe
numer
benefit
like
low
toxic
effect
therapeut
dosag
among
nanoform
hydrogel
especi
nanogel
gain
lot
attent
emerg
innov
promis
therapeut
intervent
moreov
clinic
applic
nf
upgrad
yet
implement
strategi
requir
advanc
therapi
present
articl
focuss
hydrogel
base
drug
deliveri
system
clinic
applic
system
treat
major
infecti
diseas
infecti
diseas
caus
destruct
human
health
care
worldwid
includ
aid
tuberculosi
malaria
influenza
ebola
discuss
present
review
briefli
hiv
known
retroviru
due
revers
mechan
use
human
cell
retroviru
store
genet
inform
rna
rather
dna
seen
commonli
live
thing
hiv
obliter
lymphocyt
infect
peopl
becom
prone
infecti
organ
worst
aftermath
viru
known
death
person
gener
due
infect
rather
directli
hiv
simpler
term
mechan
understood
term
fact
soon
viru
enter
bodi
attach
numer
white
blood
cell
occur
importantli
helper
lymphocyt
activ
coordin
activ
cell
immun
system
surfac
receptor
help
hiv
attach
lymphocyt
repres
occurr
error
ie
mutat
enzym
revers
transcriptas
process
make
copi
rna
dna
increas
therebi
increas
hiv
eventu
enhanc
replic
process
short
interv
time
ie
within
day
infect
person
genit
fluid
well
blood
get
infect
simultan
reduc
number
initi
step
infect
cycl
hiv
union
viral
cover
target
cell
follow
releas
genom
cell
studi
also
reveal
hiv
enter
cell
via
endocytosi
cell
membran
awar
occurr
hiv
infect
still
low
among
rural
popul
effort
nation
diseas
control
plan
effect
comprehens
health
educ
campaign
increas
awar
hiv
test
compris
detect
presenc
hiv
caus
acquir
immunodefici
syndrom
aid
serum
saliva
urin
detect
antibodi
antigen
rna
common
method
diagnosi
use
initi
hivtest
enzymelink
immunosorb
assay
elisa
detect
antibodi
confirmatori
test
includ
western
blot
immunofluoresc
assay
ifa
specimen
confirm
hiv
posit
specimen
show
repeatedli
reactiv
elisa
posit
ifa
reactiv
western
blot
immunoglobulin
assay
also
employ
detect
human
immunodefici
viru
type
infect
test
method
commonli
avail
nucleic
acid
test
till
invent
antiretrovir
drug
treatment
consist
treat
complic
opportunist
infect
malign
first
effect
therapi
hiv
nucleosid
revers
transcriptas
inhibitor
nrti
zidovudin
azt
invent
combin
nrti
also
success
supress
viru
long
period
thu
highli
activ
antiretrovir
therapi
haart
introduc
instead
earli
antiretrovir
therapi
art
though
wellknown
fact
nrti
major
compon
drug
cocktail
known
develop
vari
degre
myopathi
lipodistrophi
peripher
central
nervou
system
cn
neuropathi
side
effect
associ
mitochondri
toxic
nrti
side
effect
usual
associ
mitochondri
toxic
nrti
inhibit
dna
polymeras
caus
mtdna
dysfunct
reduct
dosag
target
drug
deliveri
infect
cell
demand
way
reduc
advers
toxic
effect
advanc
nanotechnolog
come
develop
nf
encapsul
antivir
drug
effici
known
long
term
therapi
moreov
dna
vaccin
known
gener
longterm
humor
cellular
immun
respons
protect
immun
accompani
mani
major
drawback
low
immunogen
clinic
test
earli
degrad
caus
dnaas
lysosom
inject
nake
dna
plasmid
exhibit
poor
distribut
ineffici
express
thu
nanocarri
drug
deliveri
system
effici
carrier
dna
mammalian
cell
increas
stabil
protect
degrad
interestingli
central
nervou
system
cn
love
target
hiv
get
infect
initi
stage
infect
hallmark
hiv
cn
asymptomat
neurocongnit
impair
mild
neurocongnit
disord
mnd
hivassoci
dementia
diseas
later
stage
infect
includ
cryptococc
mening
primari
cn
lymphonoma
past
year
research
confront
variou
neurotox
effect
present
antivir
therapi
contribut
low
effici
erad
hiv
variou
convent
strategi
safe
deliveri
differ
drug
cn
includ
liposom
nanoparticl
colloid
drug
carrier
intranas
olfactori
rout
administr
etc
antivir
treatment
often
accompani
accumul
antivir
drug
cn
due
poor
permeabl
occurr
associ
enceph
neurodegener
cn
soon
nucleosid
revers
transcriptas
inhibitor
nrti
enter
neuron
caus
inhibit
mdna
ie
mitochondri
dna
directli
affect
atp
product
result
insuffici
energi
cellular
homeostati
mainten
entir
permeabl
mitochondri
membran
depend
entir
upon
charg
hydrophob
fact
infer
hydrophil
neg
charg
compound
less
permeabl
thu
cation
nanogel
neutral
ntp
activ
increas
cellular
penetr
emerg
candid
mitochondri
toxic
nrti
greatli
reduc
combin
nanogelntp
nanodrug
nanogel
base
drug
deliveri
system
demand
explor
hiv
emphasi
given
explor
physiolog
accumul
nanogel
brain
play
import
role
pathogenesi
neuron
diseas
nanogel
modifi
use
hydrophob
moieti
mani
compound
capabl
enhanc
permeabl
bbb
cross
tight
junction
endotheli
cell
though
variou
limit
associ
need
taken
care
decreas
physic
restrict
endotheli
tight
junction
overcrowd
molecul
insid
brain
caus
flood
restrict
suppli
essenti
nutrient
owe
biodegrad
biocompat
biopolymer
nanogel
demand
deliveri
system
therapeut
intervent
cn
nanotechnolog
base
deliveri
system
includ
nanogel
found
use
overcom
challeng
bbb
integr
use
nanoform
great
enhanc
permeabl
pharmaceut
excipi
thu
target
activ
site
surfac
charg
hydrophob
nanogel
great
influenc
adsorpt
plasma
protein
thu
affect
uptak
transcytosi
polysorb
nonion
surfact
exploit
nf
brain
deliveri
endogen
protein
wide
use
antiretrovir
drug
deliveri
system
transferrin
proven
use
target
bbb
target
mechan
may
passiv
activ
importantli
cell
penetr
peptid
ie
tat
peptid
wide
use
enhanc
brain
deliveri
antihiv
drug
recent
novel
approach
demonstr
show
magnet
guid
noninvas
deliveri
drugnanocarri
central
nervou
system
method
safe
exhibit
improv
navig
bbb
nf
includ
nanogel
target
monocyt
macrophag
due
signific
role
hiv
infect
cn
possess
variou
receptor
like
mannos
residu
help
recognit
endocytosi
nanocargo
hydrogel
nanoparticl
also
term
nanogel
activ
use
dd
hydrophil
hydrophob
drug
polymer
matric
particl
high
water
absorpt
capac
effort
made
function
modifi
hydrogel
base
nf
brain
deliveri
erad
neuroaid
recent
studi
tian
et
al
show
peptid
base
nanofibr
hydrogel
nap
repres
naphthalen
acet
acid
g
repres
glycin
f
repres
phenylalanin
repres
tyrosin
napgffynm
act
nanovector
matrix
short
peptid
form
gelat
nanofibr
hydrogel
capabl
condens
dna
potenti
strong
respons
hiv
figur
studi
provid
safe
effect
platform
hiv
dna
vaccin
provid
optim
cellular
humor
immun
respons
anim
mice
studi
multipl
administr
rout
open
door
peptid
base
nanofibr
hydrogel
hiv
dna
vaccin
also
deliv
vaccin
drug
till
date
clinic
trial
shown
major
success
antihiv
base
gel
convent
polym
lipid
emuls
suggest
need
novel
molecular
design
anti
hiv
gel
supramolecular
hydrogel
high
demand
therapeut
recent
report
convers
antihiv
prodrug
selfdeliveri
supramolecular
hydrogel
show
great
potenti
sustain
releas
anti
hiv
therapeut
li
et
al
report
develop
character
supramolecular
hydrogel
may
lead
potenti
antiinflammatori
antihiv
gel
sustain
releas
revers
transcriptas
inhibitor
eg
lamivudin
zidovudin
azt
human
immunodefici
viru
hiv
work
demonstr
novel
approach
design
hydrogel
hold
potenti
multifunct
sustain
drug
releas
antihiv
drug
selfassembl
hydrogel
biocompat
natur
abl
releas
inhibitor
also
show
wide
applic
therapeut
physiolog
condit
figur
depict
molecular
design
hydrogel
antihiv
antiinflammatori
drug
phosphat
group
introduct
phosphat
group
help
hydrogel
certain
physiolog
ph
also
allow
pap
increas
viscoelast
hydrogel
potenti
cation
nanogel
hiv
recent
explor
mani
research
group
one
import
work
led
innov
develop
biodegrad
cation
cepl
nanogel
carrier
deliveri
triphosphoryl
nrti
nucleosid
revers
transcriptas
inhibitor
nrti
known
firstlin
drug
aid
treatment
compon
multidrug
cocktail
haart
studi
present
platform
low
neurotox
high
antihiv
activ
elimin
mani
side
effect
system
administr
studi
demonstr
advantag
nanogel
base
deliveri
system
owe
small
nanocarri
prepar
selfassembl
spheric
cation
cepl
polym
network
function
modif
nanogel
modifi
brain
deliveri
pegyl
cation
nanocarri
smart
carrier
show
great
potenti
pass
bbb
pegyl
cation
nanocarri
load
neg
charg
drug
demonstr
longer
blood
circul
better
chanc
penetr
bbb
well
report
use
nrti
antivir
therapi
neurotox
difficult
erad
neuro
aid
use
innov
novel
studi
greson
et
al
demonstr
use
nanogel
base
formul
safer
altern
current
antivir
therapi
low
neurotox
excel
antivir
activ
nanonrti
report
figur
nanogel
synthes
use
peg
pei
use
crosslink
synthes
nanogel
modifi
malpegnh
mw
wt
linker
molecul
nanogel
synthes
use
carbodiimideactiv
carboxyl
pamam
dendrim
gener
excess
branch
pei
mw
obtain
pamampei
core
conjug
studi
suggest
great
potenti
nanonrti
effici
cn
deliveri
success
applic
product
nanotechnolog
use
gel
use
microbicid
compound
gener
appli
vagin
rectal
protect
sexual
transmit
infect
activ
ingredi
dendrim
exhibit
antivir
activ
hiv
herp
simplex
viru
hsv
viru
vitro
anim
model
gel
pass
phase
clinic
trial
human
give
futur
prospect
expans
phase
ii
trial
evalu
efficaci
gel
prevent
hiv
genit
infect
women
special
attent
treatment
control
hiv
insid
central
nervou
system
due
fact
anti
hiv
drug
major
limit
associ
cross
blood
brain
barrier
movement
restrict
power
enzym
numer
transport
includ
member
atp
bind
cassett
abc
solut
carrier
slc
superfamili
make
brain
viral
reserv
site
result
viral
resist
also
lead
hiv
associ
dementia
malaria
known
fatal
diseas
common
occurr
africa
affect
almost
countri
worldwid
becom
high
concern
public
health
infect
transmit
bite
femal
anophel
mosquito
main
reason
malaria
prolifer
increas
number
drug
resist
parasit
report
estim
billion
peopl
risk
malaria
among
billion
high
risk
highrisk
area
one
malaria
case
occur
per
popul
briefli
pathogenesi
malaria
best
understood
understand
mechan
includ
parasit
invas
parasit
biolog
host
defenc
diseas
human
occur
transmiss
plasmodium
sporozoit
bite
infect
anophelin
pathway
sporozoit
take
via
salivari
gland
mosquito
bloodstream
host
liver
attack
hepatocyt
occur
divis
till
format
matur
schizont
thousand
daughter
merozoit
one
caus
morbid
mortal
malaria
anemia
occur
massiv
erythrocyt
lysi
due
elev
parasitemia
immun
haemolysi
effect
diseas
manag
prompt
effici
diagnosi
essenti
common
symptom
malaria
includ
fever
bodi
ach
nausea
vomit
also
seen
common
diseas
thu
laboratori
examin
peripher
blood
microscopi
antigen
detect
polymeras
chain
reaction
pcr
accur
test
confirm
malaria
light
microscopi
one
gold
standard
use
detect
malari
infect
techniqu
accompani
quantif
densiti
parasit
infect
present
focu
better
techniqu
use
diagnosi
screen
success
detect
malari
diseas
nanomedicin
diagnost
play
signific
role
bloodless
detect
low
level
malari
parasit
prevent
spread
infecti
pathogen
requir
rapid
accur
identif
infecti
agent
proper
treatment
recent
develop
fluoresc
nanoparticl
sensit
even
singl
nanoparticl
capabl
emit
strong
enough
signal
captur
thu
enabl
earli
identif
infect
proper
effect
treatment
save
patient
also
prevent
spread
pathogen
specif
nf
develop
encapsul
therapeut
agent
gene
deliv
target
site
henc
repres
promis
strategi
boost
immun
respons
vaccin
boost
efficaci
drug
treatment
paul
ehrlich
introduc
concept
magic
bullet
accord
main
focu
specif
target
caus
agent
concept
trigger
mind
scientist
work
field
drug
discoveri
deliveri
drug
malari
infect
nation
scienc
foundat
usa
found
nanotechnolog
play
crucial
role
redesign
control
materi
dimens
nanoscal
ie
nm
technolog
use
top
bottom
process
make
nanomateri
superior
surfac
well
quantum
properti
intracellular
strewn
locat
parasit
prompt
use
nanoparticul
system
treatment
imag
vector
control
earli
diagnosi
infect
particular
attent
given
overcom
pharmacokinet
mismatch
associ
therapeut
molecul
present
section
give
insight
recent
develop
hydrogel
base
deliveri
system
malari
infect
literatur
reveal
nanoparticl
explor
drug
deliveri
antimalari
drug
includ
pheroid
lipososm
solid
lipid
nanoparticl
polymerlipid
nanoparticl
dendrim
polymer
nanoparticl
selfemulsifi
drug
deliveri
system
antimalari
drug
recent
year
hydrogel
base
system
antimalari
drug
also
explor
shown
decent
result
curcumin
describ
effect
either
alon
combin
artemisinin
deriv
mice
infect
variou
plasmodium
strain
p
falciparum
p
berghei
p
chabaudi
etc
probabl
due
immunomodulatori
action
inhibit
histon
acetyl
gener
reactiv
oxygen
speci
action
protein
report
implic
malari
infect
nanoparticl
curcumin
polymer
lipid
among
mani
novel
approach
explor
research
surmount
problem
small
size
system
provid
longer
circul
time
encapsul
drug
due
enhanc
organ
penetr
retent
biodegrad
nanoparticl
develop
intracellular
drug
deliveri
moreov
emphasi
given
stimuli
respons
deliveri
system
due
inher
characterist
like
specif
endogen
stimuli
like
lower
intestin
ph
increas
concentr
glutathion
concentr
increas
level
enzym
like
matrix
metalloproteinas
factor
influenti
cellular
level
sensit
toward
vari
ph
directli
influenc
releas
cargo
late
endosom
lysosom
cell
cytoplasm
moreov
tissu
level
seen
explor
specif
microenviornment
chang
occur
neoplast
diseas
well
inflammatori
diseas
patholog
state
like
ischemia
infect
parasit
infect
malaria
major
global
health
concern
tropic
countri
like
india
artemisinin
deriv
known
effect
treatment
antimalari
therapi
though
therapi
restrict
due
high
cost
avail
artemisinin
combin
therapi
demand
act
certain
limit
like
pharmacokinet
incompat
artemisinin
combin
drug
novel
strategi
explor
improv
function
perform
curcumin
encapsul
varieti
deliveri
system
like
nanoparticl
hydrogel
bead
liposom
emuls
biopolym
complex
dandekar
et
al
demonstr
use
nanogel
curcumin
particl
form
use
combin
hydroxyl
propyl
methyl
cellulos
hpmc
polyvinyl
pyrrolidon
pvp
studi
show
vivo
antimalari
action
compar
curcumin
control
hydrogel
nanoparticl
use
effect
adjuv
therapi
prevent
recurr
andor
reduc
dose
regular
antimalari
drug
studi
demonstr
extent
dna
damag
individu
cell
use
assay
also
known
singlecel
gel
electrophoresi
scge
sensit
indic
dna
damag
techniqu
show
fluoresc
stain
visual
comet
like
structur
circular
head
tail
extend
toward
anod
due
overal
neg
charg
damag
dna
length
intens
tail
indic
amount
dna
damag
fluoresc
intens
head
tail
measur
comet
softwar
comput
tl
tm
tmo
percent
dna
damag
anim
treat
cyclophosphamid
indic
clastogen
potenti
result
show
comet
format
observ
treatment
group
anim
either
sex
well
control
group
thu
genetox
assay
help
confirm
nongenotox
cellular
safeti
develop
hpmc
nanoparticl
curcumin
recent
literatur
reveal
function
biodegrad
polymer
hydrogel
help
aromat
dipeptid
proven
potenti
candid
control
target
deliveri
therapeut
exemplifi
effect
entrap
vitamin
like
ascorb
acid
riboflavin
vitamin
antibiot
like
ampicillin
chloramphenicol
antimalari
drug
amodiaquin
anticanc
drug
like
fludarabin
mitoxantron
import
studi
panda
et
al
demonstr
selfassembl
proteolysi
resist
aromat
dipeptid
contain
conform
constrain
residu
stabl
hydrogel
dipeptid
free
n
c
termini
hydrogel
show
characterist
selfsupport
fractalin
natur
possess
high
mechan
strength
respons
toward
environment
condit
like
ph
temperatur
ionic
strength
also
reveal
fig
gel
matrix
could
encapsul
releas
bioactiv
molecul
sustain
manner
develop
hydrogel
show
cytotox
hela
cell
line
cultur
type
synthesi
confirm
modul
function
synthesi
procedur
hydrogel
design
entrap
structur
differ
drug
molecul
suggest
entrap
process
mostli
physic
unrel
chemic
natur
recent
trend
hydrogel
technolog
suggest
great
potenti
hydrogel
drug
deliveri
diagnost
hydrogel
explor
simpl
labonchip
pcr
diagnost
malaria
overcom
challeng
impos
molecular
diagnost
face
barrier
technolog
reagent
storag
cost
effect
knowledg
subsequ
hinder
introduct
method
develop
countri
simpl
microscopi
gold
standard
malaria
diagnosi
local
health
center
restrict
resourc
malaria
diagnos
presumpt
patient
fever
new
technolog
includ
immunochromatograph
rapid
diagnost
test
rdt
provid
altern
microscopi
point
care
though
carri
certain
limit
like
decreas
sensit
lower
level
parasitaemia
inhibit
high
level
parasitaemia
prozon
effect
inabl
quantit
distinguish
malaria
speci
mix
infect
failur
detect
parasit
mutat
gene
encod
certain
target
antigen
thu
need
improvis
rdt
perform
diagnost
base
nucleic
acid
pcr
isotherm
amplif
provid
superior
sensit
hydrogel
recent
explor
dispos
plastic
chip
fig
desicc
hydrogel
requir
reagent
plasmodium
specif
pcr
chip
numer
advantag
like
lowcost
room
temperatur
storag
use
demand
rehydr
gel
unprocess
blood
moreov
perform
exce
sensit
ten
fiftyfold
current
avail
diagnost
gel
base
chip
capabl
detect
plasmodium
speci
limit
detect
plasmodium
falciparum
blood
thu
studi
contribut
frontlin
malaria
diagnosi
erad
program
preclin
trial
thu
predict
hydrogel
novel
candid
use
molecular
diagnost
platform
develop
countri
numer
preval
form
diseas
tuberculosi
tb
one
extrem
vibrant
caus
morbid
mortal
one
highli
infecti
diseas
known
primarili
spread
inhal
aerosol
droplet
expel
infect
host
first
stage
tuberculosi
occur
till
week
aerosol
get
implant
alveoli
bacteria
dissemin
lymphat
circul
region
lymph
node
lung
form
primari
ghon
complex
begin
second
stage
least
month
character
hematogen
circul
bacteria
lung
organ
stage
accompani
fatal
diseas
like
tuberculosi
mening
miliari
tuberculosi
third
stage
occur
month
delay
year
follow
acut
pain
chest
inflamm
pleural
surfac
numer
preval
form
diseas
tuberculosi
tb
one
extrem
vibrant
caus
morbid
mortal
surg
consider
attent
need
biolog
bacteria
mycobacterium
tuberculosi
mtb
infect
nanomedicin
come
new
deliveri
system
high
multidrug
resist
limit
use
combin
antibiot
wide
accept
last
mani
year
report
million
peopl
develop
activ
tuberculosi
million
death
two
major
type
tuberculosi
name
multidrugresist
mdr
extens
drugresist
xdr
tuberculosi
spread
high
rate
estim
new
case
therapeut
intervent
explor
activ
cure
tb
adjunct
chemotherapi
recombin
technolog
come
viabl
bcg
vaccin
doubl
delet
mutant
mtb
major
frontlin
drug
tb
effect
treat
combin
rifampicin
rif
isoniazid
inh
pyrazinamid
pza
ethambutol
etb
though
main
limit
exhibit
cargo
treatment
tb
long
time
durat
therapi
requir
complet
cure
patient
give
rise
patient
noncompli
decreas
attempt
success
treatment
give
rise
drug
resist
strain
well
known
fact
use
tradit
anti
tb
drug
tuberculosi
achiev
nonrepl
state
host
especi
rif
inh
etb
exclud
pza
requir
bacteri
replic
action
vashist
et
al
page
predict
nonrepl
state
believ
reduc
tuberculosi
phenotyp
resist
bactericid
antibiot
introduct
drug
resist
phenomena
follow
introduct
streptomycin
cure
tb
selman
waksman
call
worri
emerg
extens
drug
resist
strain
xdr
tuberculosi
strain
resist
least
one
secondlin
inject
drug
like
capreomycin
kanamycin
fluoroquinolon
drug
like
ciprofloxacin
levofloxacin
moxifloxacin
ofloxacin
owe
high
cost
toxic
low
efficaci
high
dosag
suggest
well
longer
time
interv
ie
month
moreov
use
second
line
anti
tubular
drug
also
provid
improv
spectrum
antibiot
still
say
strong
demand
develop
dd
use
current
antituberculosi
drug
effect
deliveri
nanomedicin
impuls
develop
deliveri
vehicl
effect
improv
treatment
tb
provid
current
overview
develop
nanomedicin
tb
highlight
use
hydrogel
base
dd
regardless
prompt
advanc
last
decad
hydrogel
technolog
yet
interconnect
area
activ
clinic
tb
research
intens
develop
nanogel
provid
effect
deliveri
pathway
sustain
demand
drug
deliveri
standin
endpoint
novel
strategi
nanomedicin
import
investig
demonstr
inhal
deliveri
poli
lacticcoglycol
acid
plga
microspher
ms
load
antituberculosi
agent
rifampicin
rfpplga
ms
alveolar
macrophag
cell
could
valuabl
drug
deliveri
system
manag
tuberculosi
fig
recent
trend
suggest
intraven
iv
administr
microparticl
mp
dimens
larger
diamet
capillari
pose
great
potenti
passiv
drug
target
pulmonari
circul
known
capillari
bed
organ
lung
act
mechan
filter
compet
entrap
mp
follow
iv
administr
necess
travers
mucu
surfact
cell
mucos
layer
encount
ventil
give
opportun
passiv
lung
target
iv
administr
addit
cellmucos
barrier
well
known
mucu
repres
signific
diffusion
barrier
microns
particl
mani
report
bio
distribut
use
pulmonari
deliveri
inject
particl
chitosan
polyethylen
glycol
peg
poli
lacticcoglycol
acid
plga
polystyren
albumin
macroaggreg
albumin
maa
one
import
studi
deshmukh
et
al
demonstr
use
new
stabil
aggreg
nanogel
particl
sanp
drug
deliveri
system
target
lung
biodistribut
studi
male
spraguedawley
rat
carri
help
ex
vivo
imag
coval
label
hilyt
dyesanp
observ
free
dye
frequent
elimin
renal
filtrat
wherea
dyesnap
accumul
insid
lung
within
min
retain
hour
fluoresc
signal
seen
cours
studi
hour
kidney
observ
lung
point
time
non
toxic
also
evalu
histopatholog
studi
use
h
e
stain
broncho
alveolar
lavag
bal
fig
investig
suggest
nanogel
serv
potenti
altern
treatment
variou
pulmonari
diseas
asthma
pneumonia
tuberculosi
dissemin
lung
cancer
one
major
known
form
tuberculosi
infect
colon
give
rise
intestin
tuberculosi
intestin
tuberculosi
colon
infect
caus
mtb
usual
treat
like
pulmonari
form
diseas
restrict
pose
recent
therapeut
long
path
antibiot
erad
infect
requir
isoniazid
inh
mg
rifampin
rmp
taken
daili
month
likelihood
bacteria
develop
treatment
though
variou
side
effect
associ
drug
like
effect
inh
rash
abnorm
liver
function
test
hepat
side
roblast
anemia
high
anion
gap
metabol
acidosi
peripher
neuropathi
rmp
hepat
liver
failur
breathless
pruritu
nausea
vomit
flulik
symptom
side
effect
push
patient
discontinu
treatment
thu
develop
acquir
drugresist
tb
cours
therapi
drugresist
tb
sever
public
health
issu
mani
develop
countri
due
high
cost
treatment
medic
requir
longer
time
interv
nano
medicin
emerg
nanocarri
characterist
increas
patient
complianc
less
side
effect
nano
carrier
increas
effect
drug
entrap
sustain
deliveri
one
recent
studi
chen
et
al
poli
methacryl
acid
pmaa
nanogel
develop
carrier
inh
rmp
twostep
approach
illustr
fig
nanogel
show
uniform
spheric
morpholog
nm
lc
inh
rmp
respect
le
inh
rmp
respect
gel
demonstr
pmaa
sustain
releas
behavior
medium
simul
gastrointestin
tract
case
iii
mechan
nanogel
demonstr
potenti
use
formul
inh
rmp
step
forward
field
treatment
multidrugresist
intestin
mtb
influenza
virus
place
famili
orthomyxovirida
negativesens
rna
segment
encrypt
known
protein
viral
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
form
root
variou
serolog
dissimilar
viru
subtyp
moreov
new
subtyp
also
identifi
ha
na
subtyp
wild
water
bird
consid
natur
host
well
reservoir
emerg
influenza
virus
major
caus
infect
domest
poultri
mammal
emphasi
better
limit
spread
earli
diagnosi
prompt
laboratori
test
diagnosi
infect
made
mackay
et
al
mani
research
group
constantli
work
new
laboratori
method
influenza
detect
includ
viru
detect
convent
viru
cultur
monitor
serolog
differenti
also
use
rtpcr
though
method
limit
high
cost
effici
biosafeti
facil
effort
made
replac
longtim
take
method
like
elisa
time
consum
well
rapid
influenza
antigen
test
qcm
biosensor
base
technolog
detect
use
aptam
diagnost
also
highlight
comparison
antibodi
due
abil
get
chemic
modifi
easi
label
stabil
basic
aptam
gener
known
artifici
nucleic
acid
ligand
use
specif
target
certain
target
amino
acid
drug
bioactiv
herein
discuss
use
hydrogel
sensit
detect
aiv
moreov
use
dna
aptam
base
hydrogel
system
biosens
applic
highlight
characterist
properti
dna
fold
uniqu
secondari
tertiari
structur
inher
biocompat
easi
synthesi
make
perfect
candid
engin
hydrogel
base
system
applic
nanomedicin
biosens
hydrogel
superior
preserv
biolog
activ
sens
materi
well
divers
substrat
embed
within
hydrogel
matrix
owe
high
load
capabl
rel
small
amount
hydrogel
could
employ
pattern
insid
surfac
modifi
microfluid
channel
would
provid
stabl
system
high
impact
studi
carri
wang
et
al
demonstr
use
hydrogel
base
qcm
aptasensor
aiv
detect
group
develop
aptamerssdna
crosslink
polymer
hydrogel
sensor
coat
materi
use
hydrogel
coat
materi
made
use
acrylamidecoaptam
titr
hau
detect
use
qcm
biosensor
figur
show
decreas
reson
frequenc
shift
detect
target
titr
hau
correspond
reson
frequenc
hz
respect
result
show
notic
signal
obtain
titr
hau
shown
typic
detect
curv
also
observ
hydrogel
possess
swell
sensor
surfac
oper
influenza
viru
bioterror
agent
prompt
recent
research
develop
novel
vaccin
strategi
handl
pandem
toughest
part
achiev
complet
protect
level
increas
spread
deadli
viru
current
vaccin
strategi
requir
time
gener
billion
monoval
dose
optimum
immun
dose
million
individu
two
dose
kill
vaccin
requir
defenc
two
main
recognis
vaccin
deadli
viru
known
kill
viru
vaccin
given
intramuscular
inject
reduc
live
vaccin
particular
nasal
spray
though
emerg
strain
viru
express
variant
antigen
epitop
urg
need
new
vaccin
develop
moreov
antigen
drift
shift
caus
loss
effect
current
influenza
viru
vaccin
show
antivir
cell
respons
may
evad
major
drawback
commerci
avail
vaccin
thu
vaccin
capac
gener
cell
respons
viral
molecul
conserv
among
variou
serotyp
influenza
viru
serv
univers
vaccin
major
concern
yet
cell
induc
vaccin
influenza
viru
cell
requir
replic
protein
immun
ineffect
interest
studi
boesteanu
et
al
develop
biopolym
encapsul
live
influenza
viru
vaccin
mice
use
subcutan
rout
administr
infect
induc
exposur
respiratori
tract
viru
well
known
last
mani
year
larg
dose
influenza
viru
intraperiton
ip
prime
anim
secondari
respons
report
infect
ip
inject
influenza
strain
induc
inflammatori
cytokin
tissu
viral
replic
weight
loss
anim
establish
subcutan
rout
administr
live
viru
sourc
overt
diseas
mice
neither
lose
weight
appear
sick
demonstr
subcutan
vaccin
mice
live
influenza
viru
found
safe
immunodefici
mice
receiv
live
influenza
viru
healthi
viral
replic
tissu
use
algin
biopolym
encapsul
live
viru
initi
provid
addit
layer
protect
aerosol
contain
live
viru
fig
led
strong
cell
mediat
immun
respons
upon
rechalleng
vaccin
mice
heterosubtyp
strain
influenza
viru
immun
respons
dedic
conserv
epitop
influenza
nucleoprotein
novel
vaccin
approach
provid
heterosubtyp
protect
mice
extrem
virul
influenza
strain
anoth
interest
work
contribut
field
intranas
vaccin
deliveri
influenza
immun
involv
use
thermal
sensit
hydrogel
develop
use
n
propyl
chitosan
chlorid
htcc
bglycerophosph
bgp
system
inject
form
hydrogel
tendenc
gelat
bodi
temperatur
enabl
prolong
resid
time
split
antigen
nasal
caviti
also
demonstr
system
enhanc
transepitheli
transport
via
paracellular
rout
due
disorgan
protein
nasal
epitheli
tissu
superior
antigenspecif
system
immun
respons
mucos
iga
immun
without
adjuv
achiev
comparison
nake
split
antigen
adjuv
antigen
figur
demonstr
potenti
htcc
hydrogel
use
noninvas
fluoresc
imag
well
observ
signal
sourc
fluoresc
label
antigen
detect
h
mice
treat
pbsantigen
detect
strong
fluoresc
intens
h
hydrogelantigen
direct
resid
time
least
h
nasal
caviti
also
show
quantit
measur
nasal
fluoresc
intens
antigen
nasal
tissu
codeliveri
hydrogel
h
comparison
sharp
decreas
observ
pb
antigen
group
antigen
retain
nasal
caviti
thu
system
also
support
fact
hydrogel
possess
enhanc
deliveri
effect
suggest
htcc
hydrogel
perfect
candid
act
adjuv
free
vaccin
deliveri
system
intranas
split
antigen
vaccin
ebola
viru
earlier
known
zair
ebola
viru
one
five
virus
within
genu
ebolaviru
major
concern
outbreak
deadli
diseas
public
health
shortag
approv
vaccin
post
exposur
treatment
partial
success
develop
therapeut
prompt
diagnost
upsurg
post
exposur
therapeut
demand
due
local
sporad
natur
ebola
infect
extent
surviv
nonhuman
primat
typic
day
infect
pose
great
challeng
treatment
reduct
viru
replic
till
immun
respons
expand
effect
control
infect
figur
present
post
therapeut
given
hour
complet
protect
experiment
infect
anim
strong
immun
adenoviru
significantli
hinder
develop
antigen
vector
nanomedicin
emerg
cut
edg
clinic
medicin
provid
synergist
approach
design
diagnost
nf
invent
mucos
vaccin
convent
intramuscular
im
subcutan
immun
suggest
effect
system
mucos
immun
respons
recent
research
group
show
mucos
deliveri
adenovirusbas
vaccin
could
effici
evad
preexist
immun
adgpz
antigen
codeliv
hydrogel
encourag
high
system
respons
well
respiratori
mucos
immun
respons
thu
exhibit
magnifi
humor
immun
recent
advanc
show
use
nanotechnolog
base
electrochem
immunosensor
base
miniatur
devic
abil
target
analyt
pm
level
research
suggest
use
miniatur
electrochem
ebola
sens
system
earli
detect
ebov
level
emphasi
develop
hydrogel
base
sensor
base
dissoci
displac
protein
bind
partner
context
hydrogel
technolog
sure
come
market
opportun
personalis
nanomedicin
though
dynam
research
develop
worldwid
control
intensif
infecti
diseas
yet
social
factor
contribut
infect
lack
adequ
human
child
health
care
high
intern
travel
demograph
well
environment
factor
includ
urban
overgrow
popul
cleanli
major
challeng
need
consid
limit
spread
deadli
diseas
st
centuri
comparison
therapeut
area
bacteria
virus
develop
resist
drug
frequent
use
antibiot
save
million
live
human
though
creat
newer
resist
strain
encourag
spread
major
challeng
lie
increas
multidrug
increas
crise
proport
us
worldwid
urg
research
design
new
formul
approach
treatment
infecti
diseas
prevent
cure
deadli
infect
discuss
far
caus
bacteria
virus
present
number
challeng
bacteria
produc
silent
infect
insid
cell
avoid
bactericid
mechan
resist
antimicrobi
drug
threat
thrust
innov
technolog
develop
novel
invent
diagnost
deliveri
approach
use
nanotechnolog
bacteri
destruct
need
effici
deliveri
better
therapeut
index
improv
therapeut
efficaci
drug
met
design
nf
import
paramet
need
taken
care
toxic
profil
nf
drug
stabil
effect
pharmacokinet
degrad
signific
challeng
field
hydrogel
base
deliveri
system
infecti
diseas
practic
clinic
applic
design
nf
multifunct
system
carri
therapeut
intervent
requir
system
possess
talent
switch
switch
basic
demand
drug
deliveri
biocompat
toxic
profil
term
safe
use
nf
human
health
care
utmost
paramet
consider
concern
hydrogel
base
nasal
spray
demand
possess
better
rout
drug
deliveri
due
enhanc
blood
circul
increas
surfac
area
adsorpt
moreov
stimuli
respons
hydrogel
base
system
still
remain
challeng
drug
deliveri
yet
lot
explor
simultan
exist
ph
gradient
oxid
environ
certain
patholog
condit
interact
cell
gene
hydrogel
underli
mechan
nanoscal
level
understood
success
translat
lab
market
applic
nanomedicin
toward
begin
new
millennium
new
nf
diagnost
technolog
would
allow
rapid
diseas
cure
diagnosi
make
thing
easier
clinician
detect
organ
caus
specif
diseas
exist
antimicrobi
resist
gene
long
term
commit
requir
fight
infecti
diseas
prospect
exploit
nanotechnolog
base
system
specif
hydrogel
due
abil
transform
specif
efficaci
present
exist
drug
well
improv
clinic
applic
still
need
pursu
effect
health
infrastructur
complet
erad
epidem
pandem
worldwid
system
act
catalyst
individu
infecti
diseas
like
malaria
slow
spread
deadli
ebola
crisi
also
destruct
trigger
hivaid
present
urgent
need
outbreak
compet
nanotechnolog
boost
pathogen
detect
deadli
ebola
viru
quick
detect
ebola
viru
import
factor
lower
circul
rate
viru
insid
patient
bodi
detect
viru
level
attain
least
day
symptom
appear
thu
fund
agenc
like
us
nation
institut
health
nih
support
research
develop
novel
diagnost
ebola
lassa
fever
acut
viral
hemorrhag
fever
first
known
nigeria
research
group
boston
univers
colleg
engin
school
medicin
collabor
compani
nextgen
assay
gener
devic
detect
diseas
mean
singl
drop
blood
patient
shine
light
viral
nanoparticl
attach
silicon
chip
classic
sever
drug
use
cure
infecti
diseas
face
import
limit
known
drug
resist
medic
commun
includ
pharmacist
chemist
urg
find
simpl
regimen
medic
sever
infecti
diseas
treatment
tuberculosi
one
major
exampl
come
emerg
multidrugresist
tb
mdrtb
known
strain
tb
suscept
first
line
medic
extens
drug
resist
tuberculosi
xdrtb
regard
untreat
goal
erad
drug
resist
tb
initi
variou
organ
world
health
organ
dot
program
direct
observ
therapi
short
cours
complet
success
stop
case
drtb
innov
develop
nf
infecti
diseas
introduc
system
could
shorten
drug
regimen
durat
lower
frequenc
dosag
improv
patienc
complianc
improv
complet
rate
thu
nf
hold
great
potenti
reduct
drug
resist
mani
infecti
diseas
versatil
form
hydrogel
manufactur
particl
form
nanogel
inhal
form
liquid
inject
form
intraven
subcutan
patch
scaffold
oral
dosag
form
make
perfect
candid
exploit
chemotherapi
drug
resist
infecti
diseas
tuberculosi
nanotechnolog
base
system
allow
increas
transcytosi
gut
lumen
cell
enhanc
intracellular
uptak
line
epithelium
improv
uptak
peyer
patch
process
reduc
loss
activ
anti
tb
chemic
bowel
prior
enter
bloodstream
radic
improv
bioavail
drug
signific
featur
hydrogel
particl
size
surfac
modul
avoid
rapid
clearanc
phagocyt
cell
thu
promot
activ
passiv
target
drug
design
hydrogel
form
control
sustain
releas
system
improv
therapeut
efficaci
significantli
reduc
side
effect
drug
major
advantag
use
hydrogel
base
system
nf
cure
infecti
diseas
abil
reach
smallest
capillari
vessel
owe
tini
volum
porou
structur
allow
penetr
across
tissu
paracellular
transcellular
pathway
noteworthi
use
biodegrad
polym
like
chitosan
cellulos
polylact
acid
plga
etc
synthesi
hydrogel
make
nf
backbon
complet
degrad
compat
monom
non
toxic
polym
owe
featur
function
abil
selfassembl
welldefin
particl
moreov
nanogel
formul
report
show
effici
load
payload
achiev
convent
nanotechnolog
base
carrier
nf
also
shown
function
adjuv
enhanc
immunostimulatori
properti
old
vaccin
increas
immunogen
vaccin
activ
immun
inflammatori
reaction
induc
memori
respons
review
explor
salient
featur
hydrogel
compet
potenti
cure
infecti
diseas
owe
tunabl
structur
function
characterist
hydrogel
obtain
modul
synthesi
approach
find
great
potenti
nanocarri
achiev
sitespecif
drug
deliveri
releas
recent
hydrogel
proven
potenti
develop
futur
person
nanomedicin
cure
infecti
diseas
inspit
signific
proven
applic
hydrogel
manag
infecti
diseas
signific
effort
made
design
develop
smart
hydrogel
nanodomain
improv
characterist
easi
process
need
develop
therapeut
target
diseas
emphasi
develop
inject
hydrogel
nasal
spray
drop
made
patient
complianc
review
call
increas
signific
effort
develop
hydrogel
base
therapeut
cargosspecif
target
diseas
test
use
anim
model
promot
translat
medicin
refer
web
version
pubm
central
supplementari
materi
biodistribut
dyesanp
follow
iv
administr
rat
administ
dyesanp
tail
vein
cathet
anim
euthan
intraperiton
inject
pentobarbit
mgkg
h
later
heart
lung
liver
spleen
kidney
remov
imag
intact
use
imag
system
reprint
refer
copyright
permiss
elsevi
